Team:Lethbridge Canada/project

From 2013hs.igem.org

(Difference between revisions)
 
(108 intermediate revisions not shown)
Line 1: Line 1:
-
<html lang="en">
+
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
-
<head>
+
<head>
-
<style>
+
<meta http-equiv="content-type" content="text/html; charset=UTF-8" />
-
a.stmp:hover {
+
<meta name="viewport" content="width=device-width" />
-
background: #ff8000;
+
<title></title>
-
border-radius: 10px;
+
-
border-width: 10px;
+
-
}
+
-
p#stmp {
+
-
color: #ff8000;
+
-
font-size: 30px;
+
-
text-align: center;
+
-
}
+
-
</style>
+
-
+
-
<title>
+
-
Lethbridge_Canada iGEM
+
-
</title>
+
-
<link rel="stylesheet" type="text/css" href="https://2013hs.igem.org/Team:Lethbridge_Canada/style?action=raw&ctype=text/css">
+
-
</head>
+
-
+
-
+
-
<body>
+
-
<div id="banner">
+
-
<img src="https://static.igem.org/mediawiki/2013hs/0/06/Lethbridgehs2013banner.png" id="banner">
+
-
</div>
+
-
<div id="nav" align="center">
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/1/15/Lethbridgehs2013home.png" alt="Home" class="nav"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/project" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/0/08/Lethbridgehs2013project.png" alt="Project" class="nav" id="selected"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/parts" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/6/63/Lethbridgehs2013parts.png" alt="Parts" class="nav"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/notebook" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/0/01/Lethbridgehs2013notebook.png" alt="Notebook" class="nav"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/safety" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/6/60/Lethbridgehs2013safety.png" alt="Safety" class="nav"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/humanpractices" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/2/26/Lethbridgehs2013humanpractices.png" alt="Human Practices" class="nav"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/team" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/e/ea/Lethbridgehs2013team.png" alt="Team" class="nav"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/attributions" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/0/0a/Lethbridgehs2013attributions.png" alt="Attributions" class="nav"></a>
+
-
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada/sponsors" class="nav"><img src="https://static.igem.org/mediawiki/2013hs/f/fc/Lethbridgehs2013sponsors.png" alt="Sponsors" class="nav"></a>
+
-
</div>
+
-
+
-
<div id="stmp">
+
-
<p id="stmp">Project</p>
+
-
<a href="#place1" class="stmp">What?</a>
+
-
<a href="#place2" class="stmp">Why?</a>
+
-
<a href="#place3" class="stmp">Constructs</a>
+
-
</div>
+
-
+
-
<div id="content">
+
-
+
-
<div class="section">
+
-
<a id="place1" class="content">
+
-
<p id="title">
+
-
What?
+
-
</p>
+
-
</a>
+
-
<p>
+
-
Oxytocin (Oxt) (pron.: /ˌɒksɨˈtoʊsɪn/) is a mammalian neurohypophysial hormone that acts primarily as a neuromodulator in the brain.
+
-
</p>
+
-
<p>
+
-
Oxytocin plays roles in sexual reproduction, in particular during and after childbirth. It is released in large amounts after distension of the cervix and uterus during labor, facilitating birth, maternal bonding, and, after stimulation of the nipples, breastfeeding. Both childbirth and milk ejection result from positive feedback mechanisms.[1]
+
-
</p>
+
-
<p>
+
-
Recent studies have begun to investigate oxytocin's role in various behaviors, including orgasm, social recognition, pair bonding, anxiety, and maternal behaviors.[2] For this reason, it is sometimes referred to as the "love hormone". There is some evidence that oxytocin promotes ethnocentric behavior, incorporating the trust and empathy of in-groups with their suspicion and rejection of outsiders.[3] Furthermore, genetic differences in the oxytocin receptor gene (OXTR) have been associated with maladaptive social traits such as aggressive behaviour.
+
-
</p>
+
-
</div>
+
 +
<script src="http://code.jquery.com/jquery-1.9.1.min.js"></script>
 +
<script src="https://2013hs.igem.org/Team:Lethbridge_Canada/jquery.slides.min?action=raw&ctype=text/javascript"></script>
 +
<link rel="stylesheet" href="https://2013hs.igem.org/Team:Lethbridge_Canada/bootstrap?action=raw&ctype=text/css" />
 +
<link rel="stylesheet" href="https://2013hs.igem.org/Team:Lethbridge_Canada/concept?action=raw&ctype=text/css" type="text/css" media="screen" />
-
<hr>
+
</head>
-
+
<body>
-
<div class="section">
+
 
-
<a id="place2" class="content">
+
<div id="project">
-
<p id="title">
+
<div id="wrapper">
-
History
+
<div id="header">
-
</p>
+
 +
<a href="https://2013hs.igem.org/Team:Lethbridge_Canada">
 +
<div id="logo_all">
 +
<img src="https://static.igem.org/mediawiki/2013hs/3/32/Leth_hs_2013_logo.png" alt="logo" />
 +
</div>
 +
<span id="title_first">Lethbridge</span>
 +
<span id="title_second">iGEM Team</span>
</a>
</a>
-
<p>
+
</div>
-
iGEM developed out of student projects conducted during MIT's Independent Activities Periods in 2003 and 2004.[3][4] Later in 2004, a competition with five teams from various schools was held. In 2005, teams from outside the United States took part for the first time.[5] Since then iGEM has continued to grow, with 130 teams entering in 2010.[6]
+
-
</p>
+
<div id="cont">
-
<p>
+
-
Because of this increasing size, in 2011 the competition was split into three regions: Europe, the Americas, and Asia (though teams from Africa and Australia also entered via "Europe" and "Asia" respectively).[7] Regional jamborees will occur during October; and some subset of teams attending those events will be selected to advance to the World Championship at MIT in November.[8]
+
<div class="cleafix>">
-
</p>
+
<div id="navigation">
-
<p>
+
<li class="navigation_project"><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/project" class="strict">Project</a>
-
In January 2012 the iGEM Foundation was spun out of MIT as an independent non-profit organization located in Cambridge, Massachusetts, USA. The iGEM Foundation supports scientific research and education through operating the iGEM competition.
+
<ul>
-
</p>
+
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/project">Description</a></li>
-
<p>
+
                                                <li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/project#video_oxy">Visual Modeling</a></li>
-
For the 2012 competition iGEM expanded into having not only the Collegiate division, but also competitions for entrepreneurs and high school students.
+
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/math">Math Model</a></li>
-
</p>
+
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/results">Results</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/wikifreeze">Wikifreeze</a></li>
 +
</ul>
 +
</li>
 +
<li class="navigation_parts decrease_opacity"><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/parts" class="strict">Parts</a></li>
 +
<li class="navigation_notebook decrease_opacity"><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/protocols" class="strict">Notebook</a>
 +
<ul>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/protocols#protocol_header">Protocols</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/notebook_march">Notebook: March</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/notebook_april">Notebook: April</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/notebook_may">Notebook: May</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/notebook_june">Notebook: June</a></li>
 +
</ul>
 +
</li>
 +
<li class="navigation_safety decrease_opacity"><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/safety" class="strict">Safety</a></li>
 +
<li class="navigation_outreach decrease_opacity"><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/outreach" class="strict">Outreach</a>
 +
<ul>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/outreach">Overview</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/presentations">Presentations</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/interviews">Interviews</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/videos">Videos</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/surveys">Parent Surveys</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/novel_study">Novel Study</a></li>
 +
</ul>
 +
</li>
 +
<li class="navigation_team decrease_opacity"><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/team" class="strict">Team</a>
 +
<ul>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/team#the_team">The Team</a></li>
 +
<li><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/team#the_advisors">The Advisors</a></li>
 +
</ul>
 +
</li>
 +
<li class="navigation_sponsors decrease_opacity"><a href="https://2013hs.igem.org/Team:Lethbridge_Canada/sponsors" class="strict">Sponsors</a></li>
 +
</ul>
 +
</div>
 +
</div>
 +
 +
 +
<div id="mainContent">
 +
 
 +
  <img class="project_banner_image" src="https://static.igem.org/mediawiki/2013hs/9/9a/Lethbridge_hs_igem_2013_banner_project.png"><br></br>
 +
 
 +
  <div id="description_contents">
 +
        <h1>Contents:</h1>
 +
  <ul>
 +
  <li><a href="#project_intro">Introduction - Why this project?</a></li>
 +
  <li><a href="#project_oxytocin">What is Oxytocin?</a></li>
 +
  <li><a href="#project_parts">Parts</a>
 +
  <ul>
 +
  <li><a href="#project_oxytocin_construct">Oxytocin-Neurophysin I Construct/Gene</a></li>
 +
  <li><a href="#project_nec1_construct">Nec I Construct/Gene</a></li>
 +
  </ul>
 +
  </li>
 +
  <li><a href="#project_assays">Assays/Promoters - Statistical Results</a></li>
 +
  <li><a href="#math">Math Modeling</a></li>
 +
  <li><a href="#project_conclusion">Conclusion</a></li>
 +
  </ul>
 +
  </div>
 +
 
 +
  <div id="project_intro">
 +
 
 +
  <h1>Introduction:</h1>
 +
 
 +
  <p>Our project is to create a natural form of Oxytocin that can be used for widespread research and medical application. Oxytocin has a very short half-life, ranging anywhere from approximately three to ten minutes, in its active form <sup><a href="#project_references">(1)</a></sup>. This means that over time, the hormone will degrade very quickly and become unusable. The goal is produce the hormone, attached to it's carrier molecule, Neurophysin I in order to prevent the breakdown of Oxytocin. We hope that our project will be able to make Oxytocin more readily available for study.</p><br></br>
 +
 
 +
  </div>
 +
 
 +
  <div id="project_oxytocin">
 +
 
 +
  <h1>What is Oxytocin?:</h1>
 +
 
 +
  <p>Oxytocin is a hormone that has many effects on the body. Physically, it is known to stimulate uterine contractions, aiding the mother in birth <sup><a href="#project_references">(2)</a></sup>. However, Oxytocin also has many other applications with social interaction. Oxytocin helps foster a bond between the mother and child, and stimulates a positive reaction when participating in social interaction. At present, Oxytocin is not comprehensively understood by researchers regarding its wide and varied effects. Many studies have been undertaken to determine exactly how Oxytocin interacts with the body. In some cases, Oxytocin provides results suggesting that it will enhance the social behaviours of animals and humans when added to their system <sup><a href="#project_references">(3)</a></sup>. It is thought to improve facial recognition between face-to-face interactions, assisting in picking up on emotional cues<sup><a href="#project_references">(4)</a></sup>. If true, Oxytocin could eventually aid people with social bonding disorders, such as autism<sup><a href="#project_references">(5)</a></sup>, schizophrenia, and depression. Yet in some cases, it also produced results indicating individuals would isolate themselves into groups and promote exclusionary behavior<sup><a href="#project_references">(6)</a></sup>. Researchers also do not have a strong case towards whether Oxytocin will have positive or negative effects in the human body when used long term, as so far all experiments have only dealt with short term effects on humans. All things considered, having cheap and efficient Oxytocin to study could greatly enhance our knowledge of the hormone, and eventually our ability to treat certain social disorders.</p>
 +
  <img id="oxytocin_smooth" src="https://static.igem.org/mediawiki/2013hs/b/bb/Lethbridge_HS_iGEM_2013_OxyMol_Pic_Horizontal.png">
 +
  </div><br></br>
 +
 
 +
  <div id="project_parts">
 +
 
 +
  <h1>Parts:</h1>
 +
 
 +
 
 +
  <div id="project_oxytocin_construct">
 +
 
 +
  <h2>Oxytocin-Neurophysin I:</h2>
 +
 
 +
  <p>We accomplish the task of synthesizing Oxytocin though the use of two separate constructs. The first, is a system designed from maximal gene expression in order to produce the greatest amount of hormone possible. In nature, Oxytocin is produced with its carrier molecule: Neurophysin I. This carrier protein inhibits the degradation of Oxytocin; prolonging its shelf-life. This combined compound is known as prepro-oxyphysin and is the gene of interest expressed in our system.</p>
 +
 
 +
  <p>However, some modifications needed to be made to the gene during synthesis. First, a signal sequence native to <i>E. coli</i>, was added to allow for the protein to be exported beyond the cell due to the lack of Golgi Apparatus within the organism. The prepro-oxyphysin protein begins with a cysteine which forms a disulfide bond with with another cysteine later in the protein. In mammalian cells, prepro-oxyphysin is preceded by a signal sequence that guides it to the Golgi apparatus. This signal sequence is then cleaved from prepro-oxyphysin. We mimicked this by using the signal sequence PelB<sup><a href="#project_references">(8)</a></sup>. This directed the prepro-oxyphysin through the inner membrane of <i>E. coli</i> and the signal sequence is cleaved as it passes through the membrane. This makes the first cysteine in prepro-oxyphysin available to for a disulfide bond. Additionally, histidine tags were added to the end of the protein to allow us to purify it using nickel-sepharose and detect it using mouse anti-his antibodies.</p>
 +
 
 +
  <img class="construct_project_img" src="https://static.igem.org/mediawiki/2013hs/8/85/Leth_hs_2013_general_construct_diagram_v2.png" alt="Construct Diagram" />
 +
 
 +
  <p>J23100_B0032_OXT_B0015</p>
 +
 
 +
  </div><br></br>
 +
 
 +
  <div id="project_nec1_construct">
 +
 
 +
  <h2>NEC I Enzyme:</h2>
 +
 
 +
  <p>The function of the second construct is to produce NEC I at a rate such that the numerical amount of NEC I interacting with prepro-oxyphisin would be optimized. The aim of this to increase the efficiency of the system and to reduce the cost of producing NEC I, as it is a very large protein and it may be difficult to produce in high amounts in <i>E. coli</i>. In order to do this, we made use of mathematical modelling to determine the correct ratio of enzyme to protein. Like the first construct, histidine tags were added after the enzyme in order to purify and detect it.</p>
 +
 
 +
  <img class="construct_project_img" src="https://static.igem.org/mediawiki/2013hs/4/48/Leth_hs_2013_Nec1_diagram_v2.png" alt="Construct Diagram" />
 +
 
 +
  <p>We are taking the first steps toward optimizing the expression rate of NEC I by creating a model with different efficiency promoters followed by a high efficiency RBS and the fluorescent protein mCherry. We aim to monitor the expression rate of mCherry behind each promoter, and use this alongside our mathematical model to predict the amount of NEC I we can produce. We will keep in mind that the NEC I protein is significantly larger than mCherry when we are making our comparison.</p>
 +
 
 +
  <img class="construct_project_img" src="https://static.igem.org/mediawiki/2013hs/6/69/Lethbridge_HS_iGEM_2013_mCherry_construct.png" alt="Construct Diagram" />
 +
 
 +
  </div><br></br>
 +
 
 +
  </div>
 +
 
 +
  <div id="project_assays">
 +
 
 +
  <h1>Assays:</h1>
 +
   
 +
  <p>Head over to the <a href="https://2013hs.igem.org/Team:Lethbridge_Canada/results">Results Page</a> to see how everything turned out!</p><br></br>
 +
 
 +
  </div>
 +
 
 +
  <div id="math">
 +
 
 +
  <h1>Math Modeling:</h1>
 +
   
 +
  <p>For our project, we attempted to model the protein output of our cells. This would help us in finding the correct ratio of enzyme to protein to express. The full explanation as to how the math model works can be found on our <a href="https://2013hs.igem.org/Team:Lethbridge_Canada/math">Math Model</a> page.</p>
 +
    <img src="https://static.igem.org/mediawiki/2013hs/e/e4/Leth_hs_2013_complete.png" />
 +
  </div><br></br>
 +
 
 +
        <div id="video_oxy">
 +
                <h1>Visual Modeling</h1>
 +
                  <iframe width="640" height="360" src="http://www.youtube.com/embed/4xP_G6-Ur9M" frameborder="0" allowfullscreen></iframe>
 +
        </div>
 +
<p>When I built the visual model, I encountered a few challenges. The first problem was converting the 3D PDB files using the software “VMD” to the proper format for Autodesk Maya (3D software) to work. Luckily, I was not the one who had to deal with the conversions because I wasn’t able to convert the file on my own anyway. Just downloading and converting the file took a whole week to figure out. I later found the plug in ePMV which was able to convert the files into Maya format. The second challenge was to learn enough of the Autodesk Maya I needed so that I could animate and pan around the proteins. My first tries were very jumpy and the animations were too dark. Finally I decided to place a camera on a motion track which was another too-complicated ordeal and with the camera on the track. After I added lights to either side, I had very smooth panning and bright conditions for the animation. My third problem was rendering the file. Before I did this project, I knew that rendering would be a pain, but I didn't know how much. It took hours to set the render settings properly and hours after that to render the video to a 720p resolution. I was satisfied with my work however because it was smooth, not too fast, and looked professional enough in my eyes. My last problem was the worst problem. Frustrated doesn't even describe the video editing portion. In my mind I thought that what I rendered in the video was in the wrong order because it showed the NEC I protein first and then the Oxytocin-Neurophysin I. So I reversed the video in Sony Vegas and added text, but I had issues with a lot of fragmenting in the video even after I rendered it. This resulted in approximately 5 hours of tweaking and trying to remove the massive amounts of fragments on the video. Finally, I scrapped the project and opened it up again to learn that it was because I reversed the video that it did that. After all of that I hammered out the video that is up on Youtube today and added some filtered music very quietly to have ambience to the video. I then rendered the video and placed it on Youtube.</p><br></br>
 +
  <p style="text-align: right;">- Joseph Adams</p>
 +
  <div id="project_conclusion">
 +
 
 +
  <h1>Conclusion:</h1>
 +
 
 +
  <p>In the end, we hope to produce a working Oxytocin-NeurophysinI (prepro-oxyphysin) construct along with a functional NEC I construct. If we manage to attain those two constructs, we can obtain the hormone Oxytocin in its natural form. It is our hope that our construct will be able to substantially reduce the cost of producing Oxytocin in the commercial environment. Once we have constructed a working system, sending our parts into the parts registry will help future researchers study the effects that Oxytocin has in a mammalian system using the naturally occurring form of the hormone.</p>
 +
 
 +
 
 +
  </div><br></br>
 +
 
 +
  <div id="project_references">
 +
 
 +
  <h1>References</h1>
 +
 
 +
    <ol>
 +
      <li><a href="http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa4fb554-cb54-4c44-9955-1c382a2daa90">Oxytocin Half Life</a></li>
 +
      <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1465771/pdf/jphysiol02057-0001.pdf">Dale HH (May 1906)</a></li>
 +
      <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/18655894">Heinrichs M, Domes G</a></li>
 +
      <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/23575742">Shahrestani S, Kemp AH, Guastella AJ</a></li>
 +
      <li><a href="http://www.ncbi.nlm.nih.gov/pubmed/23643748">Prosocial effects of oxytocin in two mouse models of autism spectrum disorders</a></li>
 +
      <li><a href="http://www.pnas.org/content/89/13/5981.full.pdf">Oxytocin
 +
receptor distribution reflects social organization in monogamous and polygamous voles</a></li>
 +
      <li><a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0063442">Singh et al</a></li>
 +
    </ol>
 +
 
 +
  </div><br></br>
 +
 
 +
 +
</div>
 +
</div>
</div>
</div>
-
+
</div>
-
<hr>
+
</body>
-
+
-
<div class="section">
+
-
<a id="place3" class="content">
+
-
<p id="title">
+
-
BioBricks
+
-
</p>
+
-
</a>
+
-
<p>
+
-
BioBrick standard biological parts are DNA sequences of defined structure and function; they share a common interface and are designed to be composed and incorporated into living cells such as E. coli to construct new biological systems. BioBrick parts represent an effort to introduce the engineering principles of abstraction and standardization into synthetic biology. The trademarked words BioBrick and BioBricks are correctly used as adjectives (not nouns) and refer to a specific "brand" of open source genetic parts as defined via an open technical standards setting process that is led by the BioBricks Foundation.
+
-
</p>
+
-
<p>
+
-
BioBrick parts were introduced by Tom Knight at MIT in 2003.[1][2] Drew Endy,[3] now at Stanford, and Christopher Voigt, at MIT, are also heavily involved in the project. A registry of several thousand public domain BioBrick parts is maintained by Randy Rettberg team at http://partsregistry.org. The annual iGEM competition promotes the BioBrick parts concept by involving undergraduate and graduate students in the design of biological systems.
+
-
</p>
+
-
<p>
+
-
One of the goals of the BioBricks project is to provide a workable approach to nanotechnology employing biological organisms. Another, more long-term goal is to produce a synthetic living organism from standard parts that are completely understood.[4]
+
-
</p>
+
-
<p>
+
-
Each BioBrick part is a DNA sequence held in a circular plasmid; the "payload" of the BioBrick part is flanked by universal and precisely defined upstream and downstream sequences which are technically not considered part of the BioBrick part. These sequences contain six restriction sites for specific restriction enzymes (at least two of which are isocaudomers), which allows for the simple creation of larger BioBrick parts by chaining together smaller ones in any desired order. In the process of chaining parts together, the restriction sites between the two parts are removed, allowing the use of those restriction enzymes without breaking the new, larger BioBrick apart.[5] To facilitate this assembly process, the BioBrick part itself may not contain any of these restriction sites.[1]
+
-
</p>
+
-
<p>
+
-
There are three levels of BioBrick parts: "parts", "devices" and "systems".[3] "Parts" are the building blocks and encode basic biological functions (such as encoding a certain protein, or providing a promoter to let RNA polymerase bind and initiate transcription of downstream sequences); "devices" are collections of parts that implement some human-defined function (such as a riboregulator producing a fluorescent protein whenever the environment contains a certain chemical);[6] "systems" perform high-level tasks (such as oscillating between two colors at a predefined frequency).
+
-
</p>
+
-
<p>
+
-
Example BioBrick systems honored at previous iGEM competitions include:
+
-
</p>
+
-
<p>
+
-
E. coli detector for arsenic that responds with pH change;
+
-
</p>
+
-
<p>
+
-
E. coli producer of various scents such as banana or mint;
+
-
</p>
+
-
<p>
+
-
human cell line engineered to inhibit excessive response to Toll-like receptor activation, so as to avoid sepsis.
+
-
</p>
+
-
<p>
+
-
Two measures for the performance of biological parts have been defined by Drew Endy's team: PoPS or Polymerase per second, the number of times a RNA polymerase passes by a certain DNA point per second; and RiPS or Ribosomal initiations per second, the number of times a ribosome passes a certain point on mRNA each second.[7]
+
-
</p>
+
-
<p>
+
-
The original BioBricks only use two of the compatible restriction enzymes XbaI and SpeI. Recently, Xu et al [8] have expanded this concept and used four of the compatible restriction enzymes AvrII, XbaI, SpeI and NheI. The engineered ePathBrick vectors comprise four compatible restriction enzyme sites allocated on strategic positions so that different regulatory control signals can be reused and manipulation of expression cassette can be streamlined. Specifically, these vectors allow for fine-tuning gene expression by integrating multiple transcriptional activation or repression signals into the operator region. At the same time, ePathBrick vectors support the modular assembly of multi-gene metabolic pathways and combinatorial generation of pathway diversities with three distinct configurations.
+
-
</p>
+
-
</div>
+
-
+
-
<hr>
+
-
+
-
<div class="section">
+
-
<a id="place4" class="content">
+
-
<p id="title">
+
-
DNA
+
-
</p>
+
-
</a>
+
-
<p>
+
-
Deoxyribonucleic acid (DNA) is a molecule that encodes the genetic instructions used in the development and functioning of all known living organisms and many viruses. Along with RNA and proteins, DNA is one of the three major macromolecules essential for all known forms of life. Genetic information is encoded as a sequence of nucleotides (guanine, adenine, thymine, and cytosine) recorded using the letters G, A, T, and C. Most DNA molecules are double-stranded helices, consisting of two long polymers of simple units called nucleotides, molecules with backbones made of alternating sugars (deoxyribose) and phosphate groups (related to phosphoric acid), with the nucleobases (G, A, T, C) attached to the sugars. DNA is well-suited for biological information storage, since the DNA backbone is resistant to cleavage and the double-stranded structure provides the molecule with a built-in duplicate of the encoded information.
+
-
</p>
+
-
<p>
+
-
These two strands run in opposite directions to each other and are therefore anti-parallel, one backbone being 3' (three prime) and the other 5' (five prime). This refers to the direction the 3rd and 5th carbon on the sugar molecule is facing. Attached to each sugar is one of four types of molecules called nucleobases (informally, bases). It is the sequence of these four nucleobases along the backbone that encodes information. This information is read using the genetic code, which specifies the sequence of the amino acids within proteins. The code is read by copying stretches of DNA into the related nucleic acid RNA in a process called transcription.
+
-
</p>
+
-
<p>
+
-
Within cells, DNA is organized into long structures called chromosomes. During cell division these chromosomes are duplicated in the process of DNA replication, providing each cell its own complete set of chromosomes. Eukaryotic organisms (animals, plants, fungi, and protists) store most of their DNA inside the cell nucleus and some of their DNA in organelles, such as mitochondria or chloroplasts.[1] In contrast, prokaryotes (bacteria and archaea) store their DNA only in the cytoplasm. Within the chromosomes, chromatin proteins such as histones compact and organize DNA. These compact structures guide the interactions between DNA and other proteins, helping control which parts of the DNA are transcribed.
+
-
</p>
+
-
</div>
+
-
+
-
</div>
+
-
</body>
+
</html>
</html>

Latest revision as of 17:00, 20 July 2013



Introduction:

Our project is to create a natural form of Oxytocin that can be used for widespread research and medical application. Oxytocin has a very short half-life, ranging anywhere from approximately three to ten minutes, in its active form (1). This means that over time, the hormone will degrade very quickly and become unusable. The goal is produce the hormone, attached to it's carrier molecule, Neurophysin I in order to prevent the breakdown of Oxytocin. We hope that our project will be able to make Oxytocin more readily available for study.



What is Oxytocin?:

Oxytocin is a hormone that has many effects on the body. Physically, it is known to stimulate uterine contractions, aiding the mother in birth (2). However, Oxytocin also has many other applications with social interaction. Oxytocin helps foster a bond between the mother and child, and stimulates a positive reaction when participating in social interaction. At present, Oxytocin is not comprehensively understood by researchers regarding its wide and varied effects. Many studies have been undertaken to determine exactly how Oxytocin interacts with the body. In some cases, Oxytocin provides results suggesting that it will enhance the social behaviours of animals and humans when added to their system (3). It is thought to improve facial recognition between face-to-face interactions, assisting in picking up on emotional cues(4). If true, Oxytocin could eventually aid people with social bonding disorders, such as autism(5), schizophrenia, and depression. Yet in some cases, it also produced results indicating individuals would isolate themselves into groups and promote exclusionary behavior(6). Researchers also do not have a strong case towards whether Oxytocin will have positive or negative effects in the human body when used long term, as so far all experiments have only dealt with short term effects on humans. All things considered, having cheap and efficient Oxytocin to study could greatly enhance our knowledge of the hormone, and eventually our ability to treat certain social disorders.



Parts:

Oxytocin-Neurophysin I:

We accomplish the task of synthesizing Oxytocin though the use of two separate constructs. The first, is a system designed from maximal gene expression in order to produce the greatest amount of hormone possible. In nature, Oxytocin is produced with its carrier molecule: Neurophysin I. This carrier protein inhibits the degradation of Oxytocin; prolonging its shelf-life. This combined compound is known as prepro-oxyphysin and is the gene of interest expressed in our system.

However, some modifications needed to be made to the gene during synthesis. First, a signal sequence native to E. coli, was added to allow for the protein to be exported beyond the cell due to the lack of Golgi Apparatus within the organism. The prepro-oxyphysin protein begins with a cysteine which forms a disulfide bond with with another cysteine later in the protein. In mammalian cells, prepro-oxyphysin is preceded by a signal sequence that guides it to the Golgi apparatus. This signal sequence is then cleaved from prepro-oxyphysin. We mimicked this by using the signal sequence PelB(8). This directed the prepro-oxyphysin through the inner membrane of E. coli and the signal sequence is cleaved as it passes through the membrane. This makes the first cysteine in prepro-oxyphysin available to for a disulfide bond. Additionally, histidine tags were added to the end of the protein to allow us to purify it using nickel-sepharose and detect it using mouse anti-his antibodies.

Construct Diagram

J23100_B0032_OXT_B0015



NEC I Enzyme:

The function of the second construct is to produce NEC I at a rate such that the numerical amount of NEC I interacting with prepro-oxyphisin would be optimized. The aim of this to increase the efficiency of the system and to reduce the cost of producing NEC I, as it is a very large protein and it may be difficult to produce in high amounts in E. coli. In order to do this, we made use of mathematical modelling to determine the correct ratio of enzyme to protein. Like the first construct, histidine tags were added after the enzyme in order to purify and detect it.

Construct Diagram

We are taking the first steps toward optimizing the expression rate of NEC I by creating a model with different efficiency promoters followed by a high efficiency RBS and the fluorescent protein mCherry. We aim to monitor the expression rate of mCherry behind each promoter, and use this alongside our mathematical model to predict the amount of NEC I we can produce. We will keep in mind that the NEC I protein is significantly larger than mCherry when we are making our comparison.

Construct Diagram


Assays:

Head over to the Results Page to see how everything turned out!



Math Modeling:

For our project, we attempted to model the protein output of our cells. This would help us in finding the correct ratio of enzyme to protein to express. The full explanation as to how the math model works can be found on our Math Model page.



Visual Modeling

When I built the visual model, I encountered a few challenges. The first problem was converting the 3D PDB files using the software “VMD” to the proper format for Autodesk Maya (3D software) to work. Luckily, I was not the one who had to deal with the conversions because I wasn’t able to convert the file on my own anyway. Just downloading and converting the file took a whole week to figure out. I later found the plug in ePMV which was able to convert the files into Maya format. The second challenge was to learn enough of the Autodesk Maya I needed so that I could animate and pan around the proteins. My first tries were very jumpy and the animations were too dark. Finally I decided to place a camera on a motion track which was another too-complicated ordeal and with the camera on the track. After I added lights to either side, I had very smooth panning and bright conditions for the animation. My third problem was rendering the file. Before I did this project, I knew that rendering would be a pain, but I didn't know how much. It took hours to set the render settings properly and hours after that to render the video to a 720p resolution. I was satisfied with my work however because it was smooth, not too fast, and looked professional enough in my eyes. My last problem was the worst problem. Frustrated doesn't even describe the video editing portion. In my mind I thought that what I rendered in the video was in the wrong order because it showed the NEC I protein first and then the Oxytocin-Neurophysin I. So I reversed the video in Sony Vegas and added text, but I had issues with a lot of fragmenting in the video even after I rendered it. This resulted in approximately 5 hours of tweaking and trying to remove the massive amounts of fragments on the video. Finally, I scrapped the project and opened it up again to learn that it was because I reversed the video that it did that. After all of that I hammered out the video that is up on Youtube today and added some filtered music very quietly to have ambience to the video. I then rendered the video and placed it on Youtube.



- Joseph Adams

Conclusion:

In the end, we hope to produce a working Oxytocin-NeurophysinI (prepro-oxyphysin) construct along with a functional NEC I construct. If we manage to attain those two constructs, we can obtain the hormone Oxytocin in its natural form. It is our hope that our construct will be able to substantially reduce the cost of producing Oxytocin in the commercial environment. Once we have constructed a working system, sending our parts into the parts registry will help future researchers study the effects that Oxytocin has in a mammalian system using the naturally occurring form of the hormone.